Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

12391.1;5 PFLS-LS

Projekttitel

Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy

Projekttitel Englisch

Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy.

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy
Abstract (Englisch)	Notch is a transmembrane receptor playing a key role in cancer. Previous work at EPFL in partnership with Debiopharm has led to the development of two bioassays to identify inhibitors of the Notch pathway. EPFL, Debiopharm & Atheris have completed a CTI funded project (10917.1 PFLS-LS) to screen selected libraries in the two bioassays resulting in the identification of several novel Notch pathway inhibitory peptides. This project aims to optimize and validate (in in vitro and animal models) these peptides for further pharmaceutical development.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Optimization and pre-clinical validation of new peptides inhibiting Notch signalling for cancer therapy

Abstract
(Englisch)

Notch is a transmembrane receptor playing a key role in cancer. Previous work at EPFL in partnership with Debiopharm has led to the development of two bioassays to identify inhibitors of the Notch pathway. EPFL, Debiopharm & Atheris have completed a CTI funded project (10917.1 PFLS-LS) to screen selected libraries in the two bioassays resulting in the identification of several novel Notch pathway inhibitory peptides. This project aims to optimize and validate (in in vitro and animal models) these peptides for further pharmaceutical development.